drugset / Trial / NCT00388219

Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations

NCT00388219

Phase 1 Terminated 24 enrolled Grünenthal GmbH
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine whether Transtec (R) PRO 70 µg/h and a new buprenorphine patch formulation lead to same plasma levels of buprenorphine after single dose application

Timeline

Start
2006-10
Primary completion
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 40 mg Other

Indications

No indication recorded.